Risultati per: Standard di cura nel diabete – 2022

Annals of Internal Medicine, Ahead of Print.

Annals of Internal Medicine, Ahead of Print.

This Viewpoint discusses the public health benefits that could be gained if the US Food and Drug Administration (FDA) were to mandate very low-nicotine-content cigarettes (VLNCs).

This study examines trends in cold-related mortality overall and by demographic characteristics between 1999 and 2022 in the US.

This cross-sectional study examines demographic characteristics of adults treated at outpatient mental health treatment centers using data from the 2022 US National Survey of Drug Use and Health.

Il campione di nuoto testimonial del progetto Rete Cardiologica

Stroke, Volume 56, Issue Suppl_1, Page ATMP37-ATMP37, February 1, 2025. Introduction:Limited studies have examined racial disparities in long-term survival after acute ischemic stroke (AIS) with inconsistent findings. We examined these disparities among Medicare fee-for-service (FFS) beneficiaries in U.S.Methods:We analyzed data on 1,997,487 Medicare FFS beneficiaries aged ≥65 years hospitalized with incident AIS (ICD-10 code I63) and survived >30 days from January 1, 2000 to December 31, 2017, and were followed-up until December 31, 2022. Cox proportional hazard models estimated the adjusted hazard ratio (aHR, 95% CI) and adjusted survival curves by race/ethnicity (non-Hispanic White (White), non-Hispanic Black (Black), Hispanic and Other). Models were adjusted for age, sex, and comorbidities.Results:The median age at AIS hospitalization was 78 years (IQR 72.0-84.0); 57.0% were women; 81.8%, 10.8%, 4.8% and 2.6% were White, Black, Hispanic and Other, respectively. Over a median follow-up of 4.9-years (IQR 1.7-8.8), there were 1,738,452 all-cause deaths. Adjusted 5-year survival after AIS improved from 2000-2004 to 2015-2017 for White (46.5% (95% CI 46.4-46.6) to 50.9% (50.7-51.1)), and Black (46.0% (45.8-46.3) to 48.9% (48.3-49.2)). For Hispanic and Other, survival remained largely unchanged: 54.4% (54.1-54.8) to 54.2% (53.6-54.8)) for Hispanic and 55.9% (55.4-56.4) to 54.7% (54.0-55.5) for Other. A clear pattern of long-term survival after AIS emerged by race/ethnicity showing similar survival between Hispanic and Other and between White and Black people (Figure). Stroke mortality risk was ~25% higher for White and Black compared to Hispanic and Other (aHR 1.25 (1.24-1.26)). This pattern was consistent across age groups and sex.Conclusions:Long-term survival after AIS has improved for White and Black Medicare FFS beneficiaries over time, while it remained largely unchanged for Hispanic and Other groups. This indicates persistent racial disparities in stroke outcomes.

Stroke, Volume 56, Issue Suppl_1, Page ATP327-ATP327, February 1, 2025. Self-reported stroke prevalence has increased among US adults aged 18-64 over the past decade and is projected to rise. As younger stroke survivors live longer, access to healthcare is essential for the detection, treatment, and monitoring of cardiovascular disease (CVD) risk factors to prevent recurrent stroke or other acute CVD events. Adults aged 1 personal healthcare provider, the ability to afford to see a doctor in the past year, and a routine checkup within the past year).Most stroke survivors reported healthcare access: 86.3% (95% CI 85.7 – 86.8 had insurance coverage and >1 personal healthcare provider); 26.6% (95% CI 25.9 – 27.3) couldn’t afford a doctor in the past year; and 81.2% (95% CI 80.6 – 81.1) had a routine checkup in the past year. Statistically significant differences (p < 0.05) were found across all sociodemographic groups. Younger adults (aged 18-29 and 30-44), men, and those with lower education reported less healthcare access. Varying measures of access were reported across racial/ethnic groups.Overall, most stroke survivors reported access to healthcare, although opportunities exist to improve access for younger adults, men, different racial/ethnic minorities, and those with lower education. Prior access to healthcare might have contributed to stroke survival for some individuals. Continued and improved healthcare access could help prevent recurrent stroke or other acute CVD event among stroke survivors.

Stroke, Volume 56, Issue Suppl_1, Page ATMP27-ATMP27, February 1, 2025. Background:In 2022, stroke shifted from the fourth to the fifth leading cause of death in the U.S. as COVID-19 temporarily took its place. Despite this change, stroke remains a significant cause of mortality and long-term disability in the U.S. This study analyzes trends in in-hospital mortality among stroke-related hospitalizations in California from 2016 to 2022, with a particular focus on the pandemic years.Methods:This retrospective analysis utilized patient discharge data from the California Department of Health Care Access and Information, screening nearly 25 million inpatient events for stroke-related ICD-10-CM diagnosis codes (I60-I63) among individuals 20 and older. Multivariate logistic regression (MLR) analysis assessed the impact of the pre- and post-COVID-19 periods on in-hospital mortality, adjusting for confounders such as age, gender, race and ethnicity, geographic regions, and payer source. Results were interpreted using Adjusted Odds Ratios (AOR).Results:The study identified 590,801 stroke-related hospitalizations and 66,096 in-hospital deaths (11.2%). Initially, the age-and-sex-adjusted in-hospital mortality rate decreased from 28.88 per 100,000 in 2016 to 27.38 in 2019. However, with the onset of COVID-19 in 2020, the rate increased to 27.94, peaking in 2021 at 30.78 during the pandemic’s height. In 2022, the rate slightly declined to 28.30 but remained above pre-pandemic levels.Similar trends from 2016 to 2022 were observed in age-adjusted rates for males, which increased from 27.77 to 29.73, and for females, which decreased from 29.91 to 26.98. The gap between male and female mortality rates widened significantly during the pandemic, with male mortality peaking in 2021 with a difference of 3.75.MLR analysis revealed a 22.6% increase in in-hospital mortality during the post-COVID period compared to the pre-COVID period (AOR=1.23, p

Stroke, Volume 56, Issue Suppl_1, Page AWP90-AWP90, February 1, 2025. Introduction:Over the past decade, Mobile Stroke Treatment Units (MSTU) have enhanced the quality of stroke care in the United States by bringing the hospital to the patient. While MSTUs improve stroke patient outcomes compared to standard hospital care, there are still limited units operating. The implementation of a MSTU requires considerable initial and long-term investment limiting their widespread programmatic formation. We evaluated a MSTU program in Florida between August 2023 and April 2024 for comparative patient associated out of pocket costs with MSTU and standard stroke care.Methods:A discrete time Markov Chain Monte Carlo (MCMC) model was used to estimate incremental cost-savings associated with MSTU treatment compared to standard hospital care. The Markov model captured treatment costs for the care of patients at two functional levels as defined by the modified Rankin Scale (mRS). The potential cost-savings was determined by comparing the estimated costs incurred by the MSTU cohort to a counterfactual scenario of standard care of Emergency Medical Services (EMS) transport to the Emergency Department (ED). Since the model focused on the cost of patient care, costs included only billed ED, inpatient, and outpatient hospital care and services provided in the baseline year and then estimated cost of care over the next four years. All values represent 2024 dollars ($) and a 3% discount rate was applied to years two through four.Results:The MSTU treated 59 acute stroke patients with an average age of 71.86 (SD=13.78). Overall, 76% (N=45) were diagnosed with ischemic stroke, 9% with intracerebral hemorrhage (ICH), and 15% with transient ischemic attack (TIA). At discharge, 54% were independent and 46% dependent. In Year 1 (baseline), out of pocket cost differential between MSTU patients and the standard care was estimated to be $5,306 and $6,485 for the independent and dependent patients respectively. Projected future cost differentials in Years 2 to 4 were $4,571, $3,845, and $2,817 for the independent functioning cohort and $5,586, $4,700, and $4,188 for the dependent functioning cohort.Conclusion:These results suggest that the out of pocket cost for MSTU patients was significantly lower than standard care both at baseline and over the first four years post-stroke, making MSTU acute stroke management a better economic system of care for time metrics, long term patient outcomes, and cost effectiveness.

Stroke, Volume 56, Issue Suppl_1, Page ATP388-ATP388, February 1, 2025. Introduction:Embolic Stroke of Undetermined Source (ESUS) accounts for a critical proportion of all ischemic strokes. Disambiguating embolism etiology is important to improve treatment efficacy and reduce recurrent events. Patient-specific in silico models can shed valuable insights on embolus source-destination mapping. This requires reliable and accurate pre/post-stroke hemodynamic models, which benefit from integrating multiple modes of patient information from imaging and clinical records. This is a major state-of-the-art challenge. Here, we present a workflow for multi-modal data integration from standard-of-care workup towards recreating a data-rich digital twin of stroke patients.Methods:Our workflow integrates non-contrast and contrast-enhanced head-neck CT and cardiac CT, trans-thoracic echo, and perfusion imaging, along with clinical variables such as HR, systolic/diastolic volumes, and stroke locations (with NIHSS scores). Quantitative data from these sources are then integrated into a hemodynamic model by processing features such as arterial structure, inlet flow, tuned resistance boundary conditions, cardiac timing, and stroke location. Resulting hemodynamic data was used to further simulate embolus movement towards stroke site. Statistical sampling simulations using this model were conducted to evaluate the likelihood that an occlusion location corresponded to cardiogenic, aortogenic, or other arterial sources.Results:We present our complete in silico workflow, and demonstrate the outcomes using a small cohort of 5 patients acquired from a clinical database (anonymized, IRB exempt). We demonstrate that the workflow yields high-resolution space-time varying patient hemodynamic patterns. Additionally, the embolus source-destination likelihood mapping provides detailed quantitative insights on the embolism etiology in these stroke patients. These findings indicate that our workflow and resulting digital twins can be a valuable tool in addressing the current clinical challenges in discerning embolism etiology in ESUS cases.Conclusions:We introduce a pipeline of transforming raw patient-specific information from multi-modal imaging and clinical parameters into a cohesive, data-rich in silico model for embolic stroke comprising the full heart-to-brain pathway. This offers a flexible digital twin approach for elucidating stroke etiologies in patient-specific scenarios.

Stroke, Volume 56, Issue Suppl_1, Page AHUP6-AHUP6, February 1, 2025. Introduction:Prior studies have demonstrated social determinants of health (SDoH) are associated with reduced rates of intravenous thrombolysis (IVT) for acute ischemic stroke (AIS), including in disadvantaged populations. Mechanisms of disparity may include financial/resource limitations and systemic bias. Neighborhood measures of socioeconomic status are predictors of interest in stroke research, as they may influence emergency response, transportation, and health seeking behaviors. We sought to identify SDoH factors influencing time to presentation for AIS.Methods:This is a retrospective cohort study of 432 patients ages ≥18 presenting to Tufts comprehensive stroke center with AIS and last known well (LKW)

Stroke, Volume 56, Issue Suppl_1, Page ADP13-ADP13, February 1, 2025. Background:People with stroke are at high risk of dementia. There have been reductions in stroke case fatality and disability but temporal trends in the incidence and absolute burden of post-stroke dementia have not been described.Methods:We did a population-wide analysis of over 15 million people in Ontario, Canada between 2002-2022. Using linked administrative databases, we identified all 90-day dementia-free survivors of first acute ischemic stroke or intracerebral hemorrhage (ICH). We evaluated dementia incidence from 90-days after stroke onwards using a validated definition which included hospitalization, physician claims, and dementia medications. We calculated 1-year and 5-year incidence of dementia as percentages and per 100 person-years for each fiscal year, age-/sex-standardized by the 2002 population and with follow-up until March 2022. We stratified incidence trends by sex, stroke type, and severity (90-day home time of

Stroke, Volume 56, Issue Suppl_1, Page ATP299-ATP299, February 1, 2025. Introduction:Prior studies have demonstrated social determinants of health (SDH) are associated with reduced rates of intravenous thrombolysis (IVT) for acute ischemic stroke (AIS), including in disadvantaged populations. Mechanisms of disparity may include financial/resource limitations and systemic bias. Neighborhood measures of socioeconomic status are predictors of interest in stroke research, as they may influence emergency response, transportation, and health seeking behaviors. We sought to identify SDH factors influencing time to presentation for AIS.Methods:This is a retrospective cohort study of 432 patients ages ≥18 presenting to Tufts comprehensive stroke center with AIS and last known well (LKW)